Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...

Most often secondary to childhood infection, bronchiectasis is irreversible. But there are steps you can take to improve your patients’ quality of life. Bronchiectasis, which is characterized by ...

Panelists discusses how bronchiectasis differs from other respiratory diseases like asthma and COPD through symptoms, imaging findings, and pathophysiological mechanisms. Panelists discusses how the ...

Bronchiectasis is a chronic respiratory disorder characterised by irreversible dilation of the bronchi, leading to impaired mucociliary clearance, recurrent infections and progressive respiratory ...

The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the roots of the condition. What is bronchiectasis and how can the condition be ...

Please provide your email address to receive an email when new articles are posted on . Brensocatib given as 25 mg performed better than placebo when assessing rate of pulmonary exacerbations and lung ...

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses ...

— BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — BRIDGEWATER, N.J., Nov. 18, 2025 /PRNewswire/ -- Insmed Incorporated (INSM ...

— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed (INSM) to Host Investor ...

— BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — NCFB is a chronic and progressive disease that can lead to permanent lung ...